Watson Pharmaceuticals, Inc. TRELSTAR(R) DEPOT And TRELSTAR(R) LA (Triptorelin Pamoate for Injectable Suspension) Now Available Nationwide

CORONA, Calif., April 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, has made available nationwide TRELSTAR(R) DEPOT and TRELSTAR(R) LA (triptorelin pamoate for injectable suspension) for the palliative treatment of advanced prostate cancer when orchiectomy (surgical removal of the testicles) or estrogen administration are either not indicated or are unacceptable to the patient. TRELSTAR(R), a synthetic hormone that suppresses the production of testosterone in the testicles, has been approved by the United States (U.S.) Food and Drug Administration.

TRELSTAR(R) DEPOT 3.75mg and TRELSTAR(R) LA 11.25mg are sustained release, one- and three-month intramuscular injectable formulations of triptorelin pamoate, a luteinizing hormone releasing hormone (LHRH) agonist. LHRH helps modulate the production of testosterone; the growth of the prostrate is regulated in part by the level and activity of testosterone.

"We are pleased to offer patients and their physicians an effective treatment option for advanced prostate cancer that is well tolerated and convenient to use," said Allen Chao, Ph.D., Watson's Chairman, President and Chief Executive Officer. "Watson is committed to providing value and service to urologists, and our efforts are evidenced with the introduction of TRELSTAR(R)."

Proven Efficacy

Hormone treatment can be used as an alternative to orchiectomy by suppressing the production of testosterone in prostate cancer patients, which can slow the progression of the cancer. TRELSTAR(R) offers reliable, sustained testosterone suppression and durable reduction in PSA (prostate-specific antigen) levels. Clinical studies with approximately 600 patients receiving TRELSTAR(R) demonstrated that greater than 94 percent of all patients maintained castrate testosterone levels from months two through nine. These clinical studies also demonstrated reduced PSA levels by 97 percent through month nine. In a study comparing TRELSTAR(R) DEPOT to the market leading LHRH agonist, TRELSTAR(R) DEPOT demonstrated comparable efficacy.

Easy, Well Tolerated Administration

Patients participating in clinical trials reported that TRELSTAR(R) administration was well tolerated, with a low incidence of injection site pain. The most commonly reported adverse events associated with its use included hot flushes, skeletal pain, impotence and headache, consistent with LHRH agonist therapy.

TRELSTAR(R) requires no refrigeration and is administered with the innovative Clip'n'Ject(R) System, an all inclusive reconstitution system that simplifies drug administration.

In its ongoing commitment to provide urologists with the highest standards of patient care, Watson Pharmaceuticals is offering comprehensive ordering and reimbursement support through the TRELSTAR(R) Support Line. TRELSTAR(R) also has its own unique J-Code; J3315. For ordering and reimbursement information, call 866-75-J3315 or visit http://www.trelstar.com/.

About TRELSTAR(R)

TRELSTAR(R) DEPOT and TRELSTAR(R) LA (triptorelin pamoate for injectable suspension) are one- and three-month sustained-release formulations of triptorelin, an analog of luteinizing hormone releasing hormone (LHRH or GnRH) with greater potency than naturally occurring LHRH. The products are approved for the palliative treatment of advanced prostate cancer when orchiectomy or estrogen administration are either not indicated or are unacceptable to the patient. In clinical trials, the most common adverse events occurring in patients were hot flushes, skeletal pain, impotence and headache. As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing reports of anaphylactic shock and angioedema have been reported. TRELSTAR(R) is contraindicated for use in women who are or may become pregnant. For additional information, please discuss with your physician or contact Watson Medical Communications at 866-75-J3315.

About Prostate Cancer

Prostate cancer is the most common cancer in men in the U.S., excluding skin cancer, and is estimated to account for 33 percent of all new cancers diagnosed. According to the American Cancer Society, approximately 232,090 new cases of prostate cancer are expected to be diagnosed in 2005 in the U.S., with about 70 percent of cases diagnosed in men over the age of 65. Prostate cancer can be detected early through regular digital rectal examinations and PSA testing. Low PSA levels typically are found in the blood of healthy men; the amount of PSA in the blood normally increases in the presence of prostate cancer.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com/.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts about Watson are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, market acceptance of and continued demand for Watson's products, including the impact of competitive products and pricing; patents and other intellectual property rights held by competitors and other third parties; successful compliance with governmental regulations; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2004.

Clip'n'Ject(R) is manufactured by and is a registered trademark of West Pharmaceutical Services, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.

CONTACT: investors, Patty Eisenhaur of Watson Pharmaceuticals, Inc.,+1-951-493-5611; or media, Nicole Martin of FischerHealth, +1-310-577-5870,ext. 126, for Watson Pharmaceuticals, Inc.

Back to news